---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Generic, brand name and therapeutic class of product"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Generic, brand name and therapeutic class of product. Topics: Manufacturer: Celldex Therapeutics, International nonproprietary name and description, Development code: CDX-0159, and Therapeutic class: humanized IgG1 kappa anti-KIT monoclonal antibody. 4 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/generic-brand-name-and-therapeutic-class-of-product"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Generic, brand name and therapeutic class of product

<a id="heading-2.1.2.1"></a>

## 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

### Manufacturer: Celldex Therapeutics

> “CDX-0159 is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity.”

Source: [Celldex phase 1b CSU initiation release (2020)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-initiates-phase-1b-study-cdx-0159-chronic)

| Field | Quoted record |
| --- | --- |
| Sponsor | “Celldex Therapeutics” |
| Official title | “A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU1)” |

Source: [ClinicalTrials.gov NCT06445023](https://clinicaltrials.gov/study/NCT06445023)

<a id="topic-2.1.2.1-2"></a>

### International nonproprietary name and description

| Field | Quoted record |
| --- | --- |
| INN list | “Proposed INN: List 125” |
| Latin name | “barzolvolimabum” |
| English name | “barzolvolimab” |
| Description | “extracellular domain], monoclonal antibody” |
| Expression system | “produced in Chinese hamster ovary (CHO) cells, glycoform alfa” |
| Functional class | “immunomodulator” |

Source: [WHO Proposed INN List 125 (2021)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl125.pdf)

<a id="topic-2.1.2.1-3"></a>

### Development code: CDX-0159

> “Barzolvolimab (also referred to as CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is currently being studied across multiple mast cell driven diseases including:”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

<a id="topic-2.1.2.1-4"></a>

### Proprietary name

No evidence found.

<a id="topic-2.1.2.1-5"></a>

### Therapeutic class: humanized IgG1 kappa anti-KIT monoclonal antibody

> “Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT and potently inhibits its activity.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

> “Barzolvolimab (CDX-0159) is a humanized immunoglobulin G1 kappa (IgG1κ) monoclonal antibody (mAb) that binds the extracellular domain of KIT with high specificity and sub-nanomolar affinity, and allosterically inhibits activation by SCF.”

Source: [Terhorst-Molawi et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/all.15585)

> “CDX‐0159 is a humanized IgG1/κ monoclonal antibody with a modified Fc domain that was derived from CDX‐0158, a predecessor anti‐KIT antibody with an unmodified IgG1/κ backbone.”

Source: [Alvarado et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9544977/)

> “Barzolvolimab - KIT Inhibitor Program”

Source: [Celldex third quarter results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-third-quarter-financial-results-and-provides)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
